Universal CAR-T Cells for treating relapsed and refractory Multiple Myeloma

A Clinical Study Evaluating the Safety and Efficacy of Universal BCMA-Targeted CAR-T (UWD-00B) Therapy for Refractory and Relapsed Multiple Myeloma

This study is testing a new type of CAR-T cell treatment to see if it can help people with hard-to-treat multiple myeloma feel better and live longer.

Quick facts

• Phase: Early Phase 1
• Study type: Interventional
• Enrollment: 30 (estimated)
• Ages: 18 Years to 75 Years
• Sex: All
• Sponsor: Wondercel Biotech (ShenZhen) (Industry-sponsored)
• Drugs / interventions: CAR-T, chemotherapy
• Locations: 1 site (Xi'an, Shaanxi)
• Trial ID: NCT06663046 on ClinicalTrials.gov

What this trial studies

This clinical trial evaluates the safety and preliminary efficacy of universal BCMA CAR-T cells, specifically UWD-00B, in patients with refractory and relapsed multiple myeloma. Participants will undergo preconditioning chemotherapy followed by a single injection of UWD-00B cells, with subsequent monitoring for safety and efficacy over a period of at least five years. The study aims to provide a more accessible treatment option for patients who have limited responses to conventional therapies.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18-75 with relapsed or refractory multiple myeloma who have not responded to previous treatments.

Not a fit: Patients with non-relapsed multiple myeloma or those who are not eligible for CAR-T therapy may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could offer a new, effective option for patients with difficult-to-treat multiple myeloma.

How similar studies have performed: Previous studies on BCMA-targeted CAR-T therapies have shown promise, indicating potential for success with this novel approach.

Eligibility criteria

Inclusion Criteria:

* The patient or their guardian understands and voluntarily signs the informed consent form and is expected to complete the study's follow-up assessments and treatments.

Age between 18 and 75 years, with no gender restrictions. Diagnosis of multiple myeloma according to the International Myeloma Working Group (IMWG) criteria.

Documented evidence of relapsed/refractory or primary refractory multiple myeloma, defined as follows:

Relapsed/Refractory: Lack of response to salvage therapy (defined as no minimal response (MR) or disease progression during treatment), or disease progression within 60 days of the last treatment, or progression after achieving MR or better.

Primary Refractory: No response (MR or better) to any previous treatment, with no clinical progression or minimal M-protein change, or meeting criteria for primary refractory progression.

Presence of measurable disease at screening by any of the following criteria: serum M-protein ≥ 1.0 g/dL, urine M-protein ≥ 200 mg/24 hours, or for light-chain myeloma without measurable disease in serum or urine, serum free light chain (FLC) ≥ 10 mg/dL with abnormal serum immunoglobulin κ/λ FLC ratio.

Resolution of prior treatment-related toxicities to Grade \<2 per CTCAE (unless related to underlying malignancy or deemed stable and not impacting safety or efficacy).

ECOG performance status 0-2 and an expected survival of more than 3 months.

Laboratory values meeting the following standards, indicating adequate organ and marrow function, with no severe hematological or organ impairment:

Serum albumin ≥ 25 g/L Hemoglobin ≥ 8.0 g/dL (without RBC transfusion in the prior 7 days; recombinant human erythropoietin permitted) Absolute neutrophil count ≥ 0.75×10⁹/L (growth factor support allowed if discontinued ≥7 days before test) Platelet count ≥ 60×10⁹/L (no platelet transfusion within 7 days) Creatinine clearance ≥ 30 mL/min/1.73 m² (using kidney disease formula or 24-hour urine collection) ALT and AST ≤ 3.0×ULN Total bilirubin ≤ 2.0×ULN (Gilbert's syndrome exception with direct bilirubin ≤ 1.5×ULN) PT and APTT \< 2×ULN Blood oxygen saturation ≥ 95%

Exclusion Criteria:

* Diagnosis or treatment of other invasive malignancies within 3 years, with the exception of curatively treated non-melanoma skin cancer or malignancies with no active disease for ≥ 3 years.

Prior anti-cancer treatments within 14 days or 5 half-lives (whichever is shorter) including targeted therapy, epigenetic therapy, or investigational drugs, monoclonal antibody therapy within 21 days, proteasome inhibitor therapy within 14 days, immunomodulators within 7 days, or radiotherapy (except if the radiotherapy field covers ≤5% of bone marrow).

Known active CNS involvement or clinical evidence of myelomatous meningitis. Diagnosis of Waldenström macroglobulinemia, POEMS syndrome, or primary AL amyloidosis at screening.

Positive for HBsAg or HBcAb with HBV DNA \>1000 copies/mL; positive for HCV antibodies, HIV antibodies, CMV DNA, syphilis, or EBV DNA.

History of severe allergies, including anaphylaxis, or known allergy to any study drugs, their components, or murine proteins.

Serious cardiac conditions, including but not limited to severe arrhythmias, unstable angina, recent myocardial infarction (within 6 months), NYHA Class III/IV heart failure, recent CABG, unexplained syncope, severe non-ischemic cardiomyopathy, or uncontrolled hypertension.

Unstable systemic diseases deemed significant by the investigator, including severe liver, renal, or metabolic disorders.

History of acute or chronic graft-versus-host disease (GVHD) or currently on immunosuppressive therapy for GVHD within 6 months prior to screening.

Active autoimmune or inflammatory neurologic diseases such as Guillain-Barré syndrome, ALS, or clinically significant cerebrovascular diseases.

Presence of urgent tumor-related emergencies requiring immediate treatment, such as spinal cord compression, bowel obstruction, leukostasis, or tumor lysis syndrome.

Uncontrolled bacterial, fungal, viral, or other infections requiring antibiotics.

Major surgery within 4 weeks prior to lymphodepletion, or planned major surgery during the study period.

Live virus vaccinations within 4 weeks prior to screening. Severe psychiatric illness. History of alcohol or substance abuse. Pregnant or lactating women, or females and males planning to conceive within 2 years post-cell infusion.

Any contraindication to study procedures or conditions deemed by the investigator to pose an unacceptable risk.

Where this trial is running

Xi'an, Shaanxi

• First Affiliated Hospital of Xi'an Jiaotong University — Xi'an, Shaanxi, China (Recruiting)

Study contacts

• Principal investigator: Pengcheng He, M.D. Ph.D. — First Affiliated Hospital Xi'an Jiaotong University
• Study coordinator: Clinical Deveopment Director

Conditions Multiple Myleoma; Refractory and Relapsed Multiple Myeloma; BCMA; REVO-U platform; Off-the-shelf CAR-T therapy